J.P. Morgan Healthcare Confab Live Blog: Day One
 

SAN FRANCISCO (TheStreet) -- It's Day One of the 32nd annual J.P. Morgan Healthcare Conference. Welcome to TheStreet's live-blog coverage which today will include presentations from Celgene (CELG), InterMune (ITMN), Gilead Sciences (GILD) and Medivation (MDVN).

Here's how this live blog is going to (hopefully) work: I will be posting news updates and analysis throughout the day, live from the presentation rooms and breakout (Q&A) sessions. You can also follow me on Twitter, my handle is @adamfeuerstein.

Your best bet is to check back into the live blog several times throughout the day. Feel free to ping me with questions and comments. I'll do my best to respond and keep the live blog as interactive as possible.

Here's my planned schedule for Monday, subject to change, of course. All times Eastern. And yes, my schedule will change. The J.P. Morgan conference is crazy like that.

Celgene 11 am
InterMune 12 pm
Biomarin (BMRN) 1:30 pm
Alnylam Pharma (ALN)Y 2:30 pm
Arena Pharma (ARNA) 4:30 pm
Gilead Sciences 5:30 pm
Clovis Oncology  (CLVS) 6:30 pm
Medivation 7:30 pm

Serious drinking 8 pm until ?

-- Reported by Adam Feuerstein in San Francisco.  

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside